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Abstract
Background: Since 2008, Tanzanian guidelines for prevention of mother-to-child-transmission of HIV (PMTCT) recommend
combination regimen for mother and infant starting in gestational week 28. Combination prophylaxis is assumed to be
more effective and less prone to resistance formation compared to single-drug interventions, but the required continuous
collection and intake of drugs might pose a challenge on adherence especially in peripheral resource-limited settings. This
study aimed at analyzing adherence to combination prophylaxis under field conditions in a rural health facility in Kyela,
Tanzania.
Methods and Findings: A cohort of 122 pregnant women willing to start combination prophylaxis in Kyela District Hospital
was enrolled in an observational study. Risk factors for decline of prophylaxis were determined, and adherence levels before,
during and after delivery were calculated. In multivariate analysis, identified risk factors for declining pre-delivery
prophylaxis included maternal age below 24 years, no income-generating activity, and enrolment before 24.5 gestational
weeks, with odds ratios of 5.8 (P=0.002), 4.4 (P=0.015) and 7.8 (P=0.001), respectively. Women who stated to have
disclosed their HIV status were significantly more adherent in the pre-delivery period than women who did not (P=0.004).
In the intra- and postpartum period, rather low drug adherence rates during hospitalization indicated unsatisfactory staff
performance. Only ten mother-child pairs were at least 80% adherent during all intervention phases; one single mother-
child pair met a 95% adherence threshold.
Conclusions: Achieving adherence to combination prophylaxis has shown to be challenging in this rural study setting. Our
findings underline the need for additional supervision for PMTCT staff as well as for clients, especially by encouraging them
to seek social support through status disclosure. Prophylaxis uptake might be improved by preponing drug intake to an
earlier gestational age. Limited structural conditions of a healthcare setting should be taken into serious account when
implementing PMTCT combination prophylaxis.
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Introduction
Worldwide, more than two million children younger than 15
years are HIV positive, with 90% of those living in Subsaharan
Africa. 370,000 children were newly infected in 2009 [1], mostly by
mother-to-child-transmission (MTCT) during pregnancy, during
delivery or after delivery via breastfeeding. Without medical
intervention, transmission rates range between 25% and 48% in
resource-limited settings [2].
For prevention of mother-to-child transmission of HIV
(PMTCT), administration of a single dose of the non-nucleoside
reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) to both
mother and newborn has shown to reduce the transmission risk by
over 40% [3,4]. Single-dosed NVP (sdNVP) is cheap and easy to
administer [4]. However, it has been shown that transmission
reduction is considerably more effective when combining sdNVP
with two nucleoside reverse transcriptase inhibitors (NRTIs), such
as zidovudine (AZT) and lamivudine (3TC) [5,6]. At the same
time, sdNVP is prone to resistance formation and might impede
subsequent treatment involving NVP or other NNRTIs [7,8],
while combining NVP with NRTIs has shown to reduce the
emergence of NNRTI-resistant mutations [8,9]. Since 2006, the
World Health Organization (WHO) therefore recommends a
triple combination prophylaxis regimen consisting of two NRTIs
(antenatal AZT, intra/postpartum AZT+3TC) and one NNRTI
(intrapartum sdNVP) as the standard PMTCT regimen wherever
this is feasible [10].
The United Republic of Tanzania is one of the poorest and least
developed countries in the world [11], and has an overall HIV
prevalence of about 6% [12]. HIV prevalence in pregnant women
is estimated at 10–16% [13]. In 2008, the Tanzanian Ministry of
Health followed the 2006 WHO guidelines for PMTCT and
changed its national standard recommendation from sdNVP to
combination prophylaxis. The recommended regimen includes
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soon as possible thereafter. With the onset of labor, women should
take sdNVP, AZT 300 mg every 3 hours, and 3TC 150 mg every
12 hours until delivery. After delivery, a postpartum tail of AZT
300 mg and 3TC 150 mg twice a day should be continued for
seven days. All newborns of HIV-positive mothers should receive
2 mg/kg sdNVP within 72 hours and a postpartum tail of 4 mg/
kg AZT twice a day for seven days if the mother took AZT during
pregnancy for four weeks or longer. Otherwise, the infant
postpartum tail should last for four weeks. In both the Tanzanian
and WHO recommendations, sdNVP only remains the minimum
prophylactic standard for PMTCT if more complex interventions
are not feasible [14]. Notably, while Tanzanian guidelines at time
of study conduction were based on 2006 WHO recommendations,
those were again revised in 2010. WHO now recommends start of
AZT intake from gestational week 14 onwards, suggesting that an
omission of sdNVP can be considered if AZT was taken for more
than four weeks before delivery [15].
Optimal drug adherence is crucial for drug effectiveness: on the
one hand, to sufficiently suppress the maternal viral load [16],
which in turn is one of the most important risk factors for MTCT
[17]. On the other hand, maladherence to antiretroviral drugs
potentially promotes the emergence of resistant viral strains which
may lead to failure of subsequent treatment [18].
Studies regarding adherence to combination prophylaxis for
PMTCT in rural, structurally limited settings are largely lacking
up to today. However, previous research on the acceptance of
simpler PMTCT regimens showed that in peripheral settings of
Tanzania, Uganda and Zambia, sdNVP was accepted by only
20–60% of HIV-positive women seeking antenatal care (ANC)
[4,19]. This allows for hypothesizing that more complex regimens
might inherit an even greater risk of suboptimal adherence in rural
areas, and that combination PMTCT prophylaxis might not bring
the expected benefit compared to sdNVP in terms of reduced
transmission rates and emerging resistance. The aim of this study
has been to gain insight into adherence to combination
prophylaxis in one exemplary district hospital in rural Tanzania,
and to identify possible challenges of adherence when implement-
ing this regimen.
Methods
The study was undertaken at Kyela District Hospital (KDH),
which is a rural health facility in Mbeya Region, Tanzania, and
has been providing PMTCT services supported by the German
Agency for Technical Co-operation since 2001. There are
approximately 130 pregnant women who approach KDH as
new ANC clients every month. While adult HIV prevalence in
Mbeya Region is found at around 8% [20], HIV prevalence
reached 18% among pregnant women in KDH in 2007
(unpublished data). Combination prophylaxis was introduced as
the standard PMTCT regimen in KDH in March 2008. KDH
was the only facility offering the extended regimen in the vicinity
at time of study conduction, while other closeby facilities offered
sdNVP only. Our study observed the routine ANC-embedded
PMTCT procedure in KDH between October 2008 and
September 2009.
The procedure comprised provider-initiated voluntary HIV-
counseling and testing of all pregnant women approaching ANC
services. Couple testing was encouraged. In HIV-positive women,
CD4-cell count was performed to assess indication for antiretro-
viral therapy (ART). Those with a CD4-cell count,200 cells/mla t
stage 1 or 2 of the WHO clinical staging [21], CD4-count,350
cells/ml at stage 3 and women at stage 4 regardless of CD4-count
were referred to ART. These women were automatically ineligible
for study participation. Women not indicated for ART were
offered combination prophylaxis according to the new Tanzanian
guidelines if not showing contraindications like severe anemia
(hemoglobin,7.5 g/dl) or granulocytopenia (granulocytes,
0.75*10
9/l) [14]. Consenting to take part in the prophylaxis
intervention was considered as PMTCT enrollment. The PMTCT
intervention required women to start AZT intake in gestational
week 28, or as soon as possible thereafter. According to Tanzanian
PMTCT guidelines, women were scheduled to collect their AZT
supply weekly at KDH for the first month of prophylaxis and
monthly thereafter. Drug collection required an ANC visit and a
subsequent visit of KDH pharmacy.
All women were strongly advised to deliver in KDH, or to
return to KDH within 72 hours postpartum if delivery elsewhere
was unavoidable. To ensure sdNVP intake at the onset of labor
regardless of the place of delivery, women having reached
gestational week 28 were handed out maternal sdNVP for possible
self-administration. For deliveries in KDH, maternity staff
dispensed drugs to mothers and newborns during hospitalization.
At discharge, mothers received AZT and 3TC tablets and infant
AZT syrup for the remaining postpartum tail to take home. In the
case of delivery elsewhere, postnatal infant sdNVP and maternal
and infant postpartum drugs to take home were dispensed upon
women’s return within 72 hours. Women who had not started
prophylaxis during pregnancy, but came to KDH for or after
delivery, were equally offered intra/postpartum prophylaxis.
Between October 2008 and July 2009, PMTCT-enrolling
women were systematically included in the observational study if
they fulfilled the eligibility criteria of written informed consent,
.18 years of age and no signs of psychological disorder.
Confidentiality of all obtained data was ensured. Study participa-
tion did not involve additional hospital visits beyond those
necessary for the PMTCT intervention.
Data collection
Standardized questionnaires for the stages of ANC, delivery and
maternity were developed by the authors and modified during a
pretesting period of one week before start of the study.
Data collection included an initial assessment of sociodemo-
graphic, socioeconomic and clinical parameters at the point of
consenting to participate in the study. Observations were then
divided into a pre-delivery and an intra/postpartum period, giving
consideration to respective different implications for adherence,
i.e. client-driven drug collection during pregnancy and provider-
driven intra/postpartum drug dispensation. All stages of data
collection were supported by a trained study nurse, ensuring the
routine workflow would not be disturbed.
For pre-delivery data collection, study participants were
interviewed during their recurrent ANC visits until delivery. The
study nurse conducted interviews in Swahili or the local language,
and took down answers in English. Pre-delivery questionnaires
focused on aspects like drug adherence, status of HIV-disclosure,
and reasons for failed drug collection in case of one or more missed
drug collection episodes. General acceptance of prophylaxis
among study participants was defined as having collected AZT
at least once in the pre-delivery period. Those who never collected
AZT during pregnancy were considered to be declining
prophylaxis. The definition of acceptance and decline was limited
to the pre-delivery period because it was assumed that drug receipt
during intra/postpartum hospitalization would not to the same
extent reflect an active acceptance process.
Intra/postpartum data collection included all study participants
who returned to KDH for delivery or within 72 hours thereafter.
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KDH intra/postpartumly were equally incorporated into this part
of observation. Maternity ward nurses, supported by the study
nurse, were trained to fill in questionnaires listing all different
drugs dispensed in the intra/postpartum period for each woman
and newborn, including postpartum tail drugs handed out to take
home. Intrapartum AZT and 3TC administration was only
observed in KDH deliveries. Study participants who had delivered
outside of KDH reported self-administration of sdNVP to staff at
their postpartum return; their questionnaires were then continued
with information on infant sdNVP intake and dispensed take-
home drugs.
Study participants who did not return to KDH for delivery or
within 72 hours postpartum were defined as lost to follow-up.
Definition and assessment of adherence
As customary for PMTCT services, drug intake was not directly
observed in most parts of the intervention. Accordingly, adherence
measures assessed drug collection and dispensation rather than
actual ingestion, except during intra/postpartum hopitalisation.
Overall adherence was defined to consist of women’s drug
collection during pregnancy (pre-delivery adherence), and drug
dispensation by staff during/after delivery including the postpar-
tum take-home tail (intra/postpartum adherence).
Pre-delivery adherence was measured by women’s medication
possession ratio (MPR) [22], which was generated from the
number of collected AZT doses divided by the targeted number of
doses between start of prophylaxis and delivery. Thus, collecting
all drugs as scheduled yielded an MPR of 100%, defined as full
adherence until delivery. In case of an unknown date of delivery,
an estimated delivery date was used to calculate the MPR.
Assessing intra/postpartum adherence was based on staff-listed
dispensation of respective drugs. Adherence to sdNVP was
measured in absolute intake numbers for mothers and newborns
as reported by nurses, or reported by women in case of maternal
self-administration. For maternal intrapartum AZT and 3TC,
adherence rates were assessed by dividing the hours covered
through dispensed drugs by the total hours of hospitalization until
delivery. Postpartum tail adherence comprised two parts: first, the
observed dispensation of AZT and 3TC to mothers and AZT to
newborns before hospital discharge, measured by hours of
hospitalization covered with drugs, and second, dispensation of
take-home doses for mother and infant after hospital discharge,
measured in absolute numbers of women and infants supplied with
thecorrect amountofdrugstotakehome. Outcome measuresofthe
different observed stages are summarized in Table 1.
Statistical methods
Data analysis was performed with a standard statistical software
package. For dichotomization of metric parameters like age and
gestational age at enrollment, cut-off-thresholds were defined by
using JRip, which is part of the open source machine learning
software WEKA 3 [23] and identifies thresholds with the most
discriminative power regarding the dependent variable. We set a
CD4-count cut-off level at #350 cells/ml due to the relevance of this
value in international guidelines [15]. For the remaining interval
variables, the median was used as cut-off threshold. Pearson’s chi
square test and Fisher’s exact test were used to compare categorical
data. To evaluate socio-demographic variables and their influence
on declining adherence, univariate odds ratios were calculated.
Variables that showed to be significant in the univariate analysis
(P,0.05) were included into a multivariate analysis using a forward
stepwise logistic regression to calculate adjusted odds ratios. For
analysis of adherence levels, adherence cut-off points of $95% and
$80% were used for comparability with other studies [24]. The
influence of sociodemographic variables on adherence values was
tested using the Mann-Whitney U-test.
Ethical considerations
The study was conducted in accordance with the Declaration
of Helsinki. It was approved by the Tanzanian National Institute
for Medical Research, by the Ethical Committee Mbeya, and by
the Ethical Committee of Charite ´-Universita ¨tsmedizin Berlin,
Germany. Written informed consent in Swahili was obtained
from all participants. Confidentiality was maintained throughout
the study.
Results
In total, 1395 women were counseled and HIV-tested in ANC of
KDH during the study period. Among 202 women identified HIV-
positive (14.5% of all tested), 72 (35.6%) did not meet the eligibility
criteria of the study, mostly because of an ART indication. From
130 eligible women, 5 moved away and were therefore referred
to another health facility, 2 had an abortion before starting
prophylaxis, and 1 withdrew her informed consent.
For the remaining cohort of 122 study participants, the following
median demographics were determined: 26 years of age (range 18–
37 years), 23 weeks of gestational age at PMTCT enrollment (range
9–36 weeks), 7 years of education duration (range 0–12 years),
30 minutes travel time to KDH (range 0–120 minutes), and 0
Tanzanian Shilling of travel costs to KDH (range 0–2000
Tanzanian Shilling). Seven women (5.7%) were counseled and
Table 1. Summary of used adherence outcome measures.
Observation phase Subgroup Drugs Adherence outcome measure
Antenatal Maternal AZT Medication possession ratio from women having started prophylaxis in ANC
Intrapartum Maternal sdNVP Intake ratio from all women observed intra/postpartumly
Maternal AZT/3TC % of hours covered with drugs from total hospitalization hours between admission and delivery*
Postpartum Maternal AZT/3TC N % of hours covered with drugs from total hospitalization hours between delivery and hospital discharge*
N % of women having received their correct take-home dose from all women observed intra/postpartumly
Infant sdNVP Intake ratio from all surviving newborns observed postpartumly
Infant AZT N % of hours covered with drugs from total hospitalization hours between delivery and hospital discharge*
N % of infants who received their correct take-home dose from all surviving infants observed postpartumly
*among hospital deliveries.
doi:10.1371/journal.pone.0021020.t001
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reached 391 cells/ml (range 200–883 cells/ml).
Forty-seven of 122 participants (38.5%) were lost to follow-up.
Among these were 24 women who declined prophylaxis from the
beginning, while 23 started prophylaxis, but failed to return to
KDH. One woman had an abortion after starting prophylaxis and
one baby died shortly after delivery. Seventy-three mother-child
pairs were observed from the point of maternal PMTCT enrollment
to the observation endpoint of maternal and infant drug supply in
the intra/postpartum period. Figure 1 shows an overview of all
undertaken analysesindifferent subgroupsand respectivedrop-outs.
Factors associated with declining combination
prophylaxis
Out of the 122 enrolled women, 35 (28.7%) declined pre-
delivery prophylaxis. From these decliners, 11 returned to KDH in
the intra/postpartum period.
In bivariate analysis, variables associated with declining pre-
delivery prophylaxis were women’s age of 23 years or below
(P,0.001), no income-generating activity (P=0.006), and a
gestational age at enrollment of 24.5 weeks or below (P,0.001).
In multivariate analysis, these variables showed to be associated
independently with the decline of prophylaxis with P values of
0.002, 0.015, and 0.001, respectively. As shown in Table 2, other
sociodemographic, economic and health-related variables, like
education, travel distance or CD4 cell count, were not significantly
associated with decline.
AZT-adherence levels before delivery
From 87 observed women having accepted prophylaxis, one
subsequently had an abortion and was excluded from analysis
(Figure 1). Among the remaining 86, the mean AZT-adherence
before delivery was 77%. 56 women (65.1%) attained at least 80%
adherence, and 43 women (50.0%) reached at least 95%
adherence (Figure 2). Full adherence until delivery was achieved
by 33 women (38.4%) who collected all AZT doses as required.
Disclosure of the HIV-status to the partner, a relative or a friend
was positively associated with adherence rates before delivery: out
of the 86 women who had started to take prophylaxis, 6 (7.0%)
had not disclosed their HIV status and were significantly less
(median 22.7%) adherent than women who had disclosed their
status (median 97.3%, P=0.004). Other variables were not
significantly correlated with adherence levels (Table 3).
Overall, 53 out of 86 participants (61.6%) were not fully
adherent, i.e. had missed at least one drug collection episode. In
34 of these (64.2%), reasons for failure in drug collection were
unknown, partly because they did not state any reason when asked
(11 women), and partly because they could not be asked due to loss
to follow-up (23 women). Among the 19 women who had stated one
ore more reasons (24 reasons mentioned altogether) for occurred
missed drug collection episodes, personal reasons were mentioned
most frequently (14/19 women, 73.7%), and included family
obligations (mentioned by 6 women), forgetting appointments
(mentioned by 4), transportation difficulties (mentioned by 3), and
incorrectdosingof tablets (onemention). At the same time, 10 ofthe
19 women (52.6%) named hospital-based reasons, i.e. incorrectly
indicated dates for the next visit (five mentions), neglected
dispensation of drugs at KDH pharmacy (three mentions), or staff
had decided to interrupt prophylaxis (two mentions).
Adherence during and after delivery
Out of 122 study participants, 74 were being observed in the
intra/postpartum period (Figure 1). From these, 63 (85.1%) had
accepted pre-delivery prophylaxis, while 11 (14.9%) women had
declined. Pre-delivery prophylaxis acceptance was significantly
associated with returning to KDH during or within 72 hours after
delivery (P,0.001).
Sixty-four of 74 intra/postpartum observed participants (86.5%)
delivered in KDH, and 10 women (13.5%) delivered at home but
returned to KDH within 72 hours postpartum.
SdNVP was taken by 67 out of the 74 women (90.5%) in the
correct time frame before delivery, 59 of these delivered in KDH,
and eight delivered at home. Sixty-nine newborns (93.2%)
received postnatal sdNVP in KDH, including 60 (93.8%) out of
64 KDH deliveries and 9 (90.0%) out of 10 home deliveries.
Regarding intrapartum AZT and 3TC, of the 64 deliveries in
KDH, 38 women (59.4%) attained at least 80% and 27 (42.2%) at
least 95% adherence. 26 women (40.6%) remained below 80%
adherence. Between the time of delivery and hospital discharge, 34
of the 64 women (53.1%) reached 80% and 24 (37.5%) reached
95% adherence. From the 63 surviving newborns, for 32 (50.8%)
at least 80% adherence was achieved, and for 12 children (19.0%)
at least 95% adherence was achieved when starting the
postpartum AZT tail during hospitalization.
From the 74 women which had either delivered in KDH or
returned there within 72 hours, 58 (78.4%) received the correct
amount of AZT and 3TC-tablets to take home, and 59 infants
(80.8% from 73 surviving) were dispensed the correct take-home
amount of AZT syrup. Achieved intra/postpartum adherence
levels for mothers and infants are depicted in Figure 2.
Overall adherence before, during and after delivery
Initially, 122 women had agreed to take combination prophy-
laxis. One had an abortion after starting prophylaxis and one child
died shortly after delivery. Out of the remaining 120 mother-child
pairs, 10 (8.3%) achieved at least 80% adherence rates in all phases
before, during and after delivery, and only one single mother-child
pair (0.8%) achieved a 95% adherence level for the entire PMTCT
intervention.
Discussion
Our observational study in a rural setting in Tanzania found
relatively low levels of adherence to combination prophylaxis in all
different PMTCT intervention phases.
Within the study population, young age and no income-
generating activity of the women were found to increase the risk
of not starting combination prophylaxis before delivery. This is in
accordancewith otherstudies,which identified similar riskfactorsto
influence the acceptance of ART [25] and of sdNVP-based
interventions [19]. Gestational age below 24 weeks at PMTCT
enrollment was discovered as an additional risk factor for declining
combination prophylaxis. An explanation for this could be the time
gap emerging for women who become enrolled in an early
pregnancy stage, but then have to wait until gestational week 28
until they can actually start prophylaxis. This time gap before drug
intake might imply that antiretroviral prophylaxis has no acute
priority, and forgetting future appointments may be likely. In
response to this problem, revised WHO-guidelines of July 2010
recommend prophylaxis start from gestational week 14 onwards,
aspiring to avoid idle time between enrollment and first drug intake
[15]. Although this requires adhering to antenatal AZT for an even
longer period of time, facilitating immediate prophylaxis start for
the case of early PMTCT enrollment will simplify the PMTCT
procedure to some extent and should be transferred into national
guidelines as soon as possible. Yet, it will be of high importance to
Adherence to PMTCT Combination Regimen
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extended antenatal AZT monotherapy.
Among those who started combination prophylaxis, every third
woman remained below an 80% adherence level in the period
before delivery. This rate underachieves results of a similar study
on ART adherence in a Zambian cohort of patients receiving
treatment for their own health, where only about 15% of patients
remained below an 80% adherence level [24]. In a previous meta-
analysis on ART adherence among general population receiving
treatment, it was reported that in 20 out of 22 studies, more than
half of the patients met the thresholds of 95% or full adherence
[26]. While those ART-related studies suggest that higher
Figure 1. Profile of cohort and analyses. This figure is illustrating the formation of the cohort and of its different subgroups, including women
observed in the antenatal period, women accepting/declining antenatal prophylaxis, women lost to follow-up (LTFU), women observed intra/
postpartumly and infants observed postpartumly. It is indicated which analyses have been performed within the respective subgroups and where the
results of those analyses are shown.
doi:10.1371/journal.pone.0021020.g001
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general ART programs can only represent an approximate
comparative value with regards to PMTCT, because the subgroup
of pregnant women involves specific implications for adherence.
More research, filling the existing knowledge gap on adherence to
PMTCT combination prophylaxis, is desirable to allow for putting
our findings into context.
In our study, the only factor significantly influencing levels of pre-
delivery adherence was HIV-status disclosure to the partner, a
relative or a friend. Status disclosure is known to relieve women
from emotional stress and to enable them to receive psychological
and material support by their social environment [27]. Especially in
rural settings, disclosure can facilitate issues like obtaining approval
from the husband as the main decision maker to seek healthcare,
and transportation to the hospital. From women who started to take
prophylaxis, 93% disclosed their status, a high rate compared to
other studies [28,29]. However, disclosure information could only
be obtained from women who returned to ANC at least once after
having been HIV-tested. Given that prophylaxis start is positively
influenced by disclosure [29], our rate is likely to be overestimated
due to the exclusion of 35 women declining prophylaxis.
Couple counseling and HIV-testing often facilitates partner
disclosure and positively influences general uptake of PMTCT
programs [30,31]. Deplorably few of our study participants were
counseled and tested together with their partner, confirming the
prevalent observation that adequate male involvement in PMTCT
is still largely missing [32]. A stronger implementation of couple
counseling and testing, and encouraging pregnant women to seek
support in their social environment through status disclosure, not
only to partners, but also to other confidants, e.g. in the form of
treatment buddies or community groups, could be effective
strategies for achieving better adherence rates [33,34].
Failure in pre-delivery adherence stands for women’s missed or
delayed hospital visits to collect drugs, which has been described as
Table 2. Risk factors for decline of pre-delivery prophylaxis.
Bivariate Mulitvariate
Variable n decline OR 0.95 CI P Chi
2 AOR P
Age
{ 122
.23 years 91 17.58% 1.000 1.000
#23 years 31 61.29% 7.422 3.011– 18.292 ,0,001 * 5.841 0.002
Education 113
,7 years 19 21.05% 1.000
$7 years 94 28.72% 1.511 0.460– 4.967 0.494
Income-gen. activity 116
Yes 44 13.64% 1.000 1.000
No 72 37.50% 3.800 1.420– 10.169 0.006 * 4.399 0.015
Marital status 114
Single 24 25.00% 1.000
Married 90 28.89% 1.182 0.422– 3.308 0.750
Gravida 122
Multigravida 113 28.32% 1.000
Primigravida 9 33.33% 1.266 0.298– 5.369 0.719 **
Gestational age
{ 122
.24.42 weeks 52 9.62% 1.000 1.000
#24.42 weeks 70 42.86% 7.050 2.501– 19.874 ,0,001 * 7.820 0.001
Last delivery 98
At home 27 29.63% 1.000
At health facility 71 32.39% 1.138 0.434– 2.984 0.793
Travel distance 121
#30 minutes 64 26.56% 1.000
.30 minutes 55 32.73% 1.345 0.610– 2.965 0.462
Transport costs 117
No 74 28.38% 1.000
Yes 43 30.23% 1.094 0.480– 2.493 0.831
CD4 cell count 122
.350 50 26.00% 1.000
#350 72 30.56% 1.252 0.559– 2.806 0.584
OD=odds ratio; CI=confidence interval; AOR=adjusted odds ratio.
{Threshold calculated with software JRip.
*Variables included into multivariate analyses.
**Fisher’s exact test.
doi:10.1371/journal.pone.0021020.t002
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self-reported adherence rates to ART among general population
receiving treatment for their own health [35,36]. We do not know
the reasons for missed drug collection episodes in the majority of
our study participants, either because they did not return to be
asked, or because they did not want to state reasons. In those who
shared their reasons for failure in collecting drugs, personal
obstacles were mentioned most frequently, but every second of
those women also stated that she failed to get drugs because of a
wrongly scheduled date for the next drug collection or reluctance
of drug dispensation by KDH staff. This demonstrates the crucial
importance of high quality training of hospital staff [37].
Staff were also responsible for providing correct doses of AZT
and 3TC at the right time during hospitalization of mother and
newborn. For only about half of the mothers and babies, at least
80% adherence was achieved. The threshold of 95%adherence was
met for less than half of the mothers and only one fifth of the babies.
At hospital discharge, only about 80% of mothers and babies
received the right amount of take-home drugs. These intra/
postpartum adherence levels indicate suboptimal staff performance,
and might partly be explained by the increased burden of work due
to the introduction of combination prophylaxis. High workload can
decrease motivation and dedication of staff, and might result in
inadequate care. Systems of rotating staff members between
departments often cause additional shortage and require continuous
training of new PMTCT staff [37,38]. Reducing staff rotation and
ensuring a close professional supervision could mitigate the shortage
of well-trained personnel, and thereby considerably contribute to
improved adherence rates during hospitalization. At the same time,
it should be noted that in some other African countries, e.g. Kenya
or Malawi,national guidelinesrecommend a simplified intrapartum
regimen, administrating one dose of 600 mg AZT or 300 mg AZT
twice daily instead of the three-hourly dosing throughout labor
[39,40],apracticewhichcouldalsoreduceintrapartumcare-related
staff burden to some extent.
More than one third of the enrolled women were lost to follow-
up, which is a larger fraction than in comparable studies on ART
and sdNVP adherence [41,42]. Notably, only 10 mother-child pairs
achieved at least 80% adherence in all phases of combination
prophylaxis, and only one pair was adherent on a 95% level. We
have targeted adherence levels of 80% and 95% for best
comparability with other findings, but in fact there is a lack of
evidence on necessary adherence levels to ensure the effectiveness of
combination prophylaxisand to prevent emergenceofresistantviral
Figure 2. Adherence levels reached for different drugs in antenatal, intrapartum and postpartum period. Adherence cut-off levels of
95% and 80% are described for women’s adherence to antenatal AZT, intrapartum AZT+3TC and postpartum AZT+3TC during hospitalization, as well
as for infant adherence to AZT during hospitalization. For pre-delivery AZT intake, an adherence level of $95% was reached by 50.0% and a level of
$80% was reached by 65.1% of women. For intrapartum AZT+3TC, adherence of $95% was reached by 42.2% of women who delivered in KDH and
adherence of $80% was reached by 59.4% of them. For postpartum AZT+3TC during hospitalization, adherence of $95% was reached by 37.5% and
adherence of $80% was reached by 53.1% of hospital-delivering women. In newborns, AZT adherence during hospitalization was $95% in 19.0%
and $80% in 50.8% of the infants. For sdNVP, proportions reflect self-reported correct intake of drug doses for mothers (90.5%) and staff-reported
correctly dispensed drug doses for newborns (93.2%). Postpartum take-home doses were dispensed correctly to 78.4% of women and 80.8% of
infants.
doi:10.1371/journal.pone.0021020.g002
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detailed adherence levels among the study population have
generally not been determined, while the trials have rather
considered percentages of women who reached full adherence
[43], or, like in the DITRAME trial, it was only assessed how many
women met a certain threshold like 80% adherence [44]. Further
research on specific necessary thresholds would be highly desirable
for a more revealing interpretation concerning implications of
adherence levels on drug effectiveness and resistance formation.
Inthenearfuture,theTanzaniangovernmentwillverylikelyalign
national PMTCT guidelines with WHO’s 2010 revised recommen-
dations, including the extension of ART-eligibility to those women
with a CD4 count below 350 instead of 200, and including ARV
intake throughout the entire breastfeeding period for infant (option
A) or mother (option B) [15]. This will imply new challenges with
regardsto adherence, particularlyfor women choosing to breastfeed.
According to WHO, 96.4% of Tanzanian infants are ever breastfed,
with median breastfeeding duration of 21.1 months [45]. This is in
compliance with PMTCT monitoring data from Mbeya Region,
where over 95% of HIV positive women preferred breastfeeding to
formula feeding (2009, data unpublished). Hence, for a mainly
breastfeeding population like in our study setting, the chosen
regimen option recommended in subsequent Tanzanian guidelines
will be a highly relevant issue in the upcoming years.
An important limitation of the study is that pre-delivery
adherence values in our analysis are based on MPRs. Although
found to be a valid measurement for the reduction of viral load
[46,47], MPRs bear the risk of overestimating real adherence values
[48,49], because the amount of handed-out drugs might differ from
the amount of actually ingested drugs. Suggesting that fewer women
than assumed might actually have taken drugs as required, this
would, however, strengthen our finding of suboptimal adherence.
Although we have chosen a representative district hospital
strictly oriented in national guidelines, local customs might cause a
systematical bias, and further research is strongly needed to assess
the validity of our findings for other regions.
In conclusion, achieving high adherence rates during all phases
of PMTCT combination prophylaxis has shown to be challenging
in the rural setting of this study. Prophylaxis uptake might be
improved by preponing drug intake to an earlier gestational age.
Our findings underline the need for additional training and
supervision for overburdened PMTCT staff as well as close
supervision for PMTCT clients, especially by encouraging them to
seek social support through status disclosure.
Combination prophylaxis for PMTCT is gradually replacing less
effective regimens in many resource-limited regions of the world.
However, the finding that only one mother-child pair managed to
receive 95% of the intended quantity of drugs in all PMTCT phases
in our study site results in a serious derogation of the assumed high
effectiveness of combination prophylaxis in rural settings. It should
be considered as a liability of health authorities to take limited
structural conditions into account when planning, implementing
and expanding combination prophylaxis for PMTCT.
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